its time, page-7

As my post suggests, to compare and contrast Solagran with others is vital in terms of eg. revenues, net income, total debt to capital, inventory turnover, recievables turnover, EPS, revenue/book value per share, net income, capital expenditure and market cap.

One you run many of these KPIs through, it then becomes easier to define a possible valuation per unit.

If we take management effectiveness to be considered only as a return on investment, Solagran has done fairly well at - 21.03% or return on investment as a 5 year average at - 22.69%. Only Scigen and Bionomics have performed better. But all are alarmingly negative.

IMO, as I have run all the variables through this type of peer analayis model, the blue sky within the current market cap becomes apparent. Interestingly, SLA has a 5yr capex growth rate of 14.26%. However, Solagran's gross margin is 79.65%, with 5 yr gross margin of 80.25, a net profit margin of -187.21 and a whopping 5 year (average) net profit margin of - 558.65.

Try these as this is the sector you are in ($35m to $65m):

Avexa Ltd
Bionomics Ltd
Living Cell Technologies Ltd
Nanosonics Ltd
Progen Pharmaceuticals Ltd
Scigen Ltd
Starpharma Holdings Ltd

All IMO of course and yes, I have time for investing.